The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Choosing between tisa-cel, liso-cel & axi-cel in LBCL
Craig W. Freyer, PharmD, BCOP, Hospital of the University of Pennsylvania, Philadelphia, PA, comments on the difficulty to compare and choose between the three FDA approved CAR-T products in large B-cell lymphoma (LBCL), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Due to significant differences between the clinical trials that evaluated these CAR-T therapies, it is difficult to compare these products. Nevertheless, Dr Freyer explains that axi-cel is often the drug of choice in young patients with a good performance status as it appears to induce better responses. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
